-
Alcorn T M, Faruki H. HIV Resistance Testing: Methods, Utility, and Limitations[J]. Mol Diagn, 2000, 5(3): 159-168. doi: 10.2165/00066982-200005030-00001
-
Conway B, Wainberg M A, Hall D. Development of drug resistance in patients receiving combinations of zidovudine, didanosine and nevirapine[J]. AIDS, 2001, 15(10): 1269-1274. doi: 10.1097/00002030-200107060-00008
-
DeGruttola V, Dix L, DoAquila R. The relation between baseline HIV drug resistance and response to antiretroviral therapy: re-analysis of retrospective and prospective studies using a standardized data analysis plan[J]. Antivir Ther, 2000, 5(1): 41-48.
-
Finzi D, Hermankova M, Pierson T. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy[J]. Science, 1997, 278(5341): 1295-300. doi: 10.1126/science.278.5341.1295
-
Jiang S L, Wang Z, Xing H. The laboratory evaluation and analysis of curative effect of anti-HIV treatment in Queshan County of Henan Province[J]. China J AIDS/STD, 2005, 11(12): 81-83.
-
Johnson A, Brun-VȦzinet F, Clotet B. Update of the Drug Resistance Mutations in HIV-1: 2005[J]. Top HIV Med, 2005, 13(1): 51-57.
-
Kantor R, Katzenstein D. Drug resistance in nonsubtype B HIV-1[J]. J Clin Virol, 2004, 29(): 152-159. doi: 10.1016/S1386-6532(03)00115-X
-
Kantor R, Shafer R W, Follansbee S. Evolution of resistance to drugs in HIV-1-infected patients failing antiretroviral therapy[J]. AIDS, 2004, 18(11): 1503-1511. doi: 10.1097/01.aids.0000131358.29586.6b
-
Li J Y, Li H P, Li L. Prevalence and evolution of drug resistance HIV-1 variants in Henan, China[J]. Cell Res, 2005, 15(11-12): 843-849. doi: 10.1038/sj.cr.7290356
-
Panel on Clinical Practices for Treatment of HIV Infection convened by the Department of Health and Human Services (DHHS). 2005. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Available at: AIDSinfo web site: http://AIDSinfo.nih.gov.
-
Pereira C F, Paridaen J T. Anti-HIV drug development--an overview[J]. Curr Pharm Des, 2004, 10(32): 4005-4037. doi: 10.2174/1381612043382459
-
Richman D D, Morton S C, Wrin T. The prevalence of antiretroviral drug resistance in the United States[J]. AIDS, 2004, 18(10): 1393-1401. doi: 10.1097/01.aids.0000131310.52526.c7
-
Selmi B, Deval J, Alvarez K. The Y181C substitution in 3'-azido-3'-deoxythymidine-resistant human immunodeficiency virus type 1reverse transcriptase suppresses the ATP-mediated repair of the 3'-azido-3'-deoxy-thymidine 5'-monophosphate-terminated primer[J]. J Biol Chem, 2003, 278(42): 40464-40472. doi: 10.1074/jbc.M302928200
-
Shafer R W. 2003. Genotypic Testing for HIV-1 Drug Resistance. Available at Stanford web site: http://hivdb.stanford.edu.
-
Shafer R W, Warford A, Winters M A. Reproducibility of human immunodeficiency virus type 1 (HIV-1) protease and reverse transcriptase sequencing of plasma samples from heavily treated HIV-1-infected individuals[J]. J Virol Methods, 2000, 86(2): 143-153. doi: 10.1016/S0166-0934(00)00144-0
-
Si X F, Huang H L, Wei M. Prevalence of drug resistance mutations among antiretroviral drug-naive HIV-1-infected patients in China[J]. Chin J Exper Clin Virol, 2004, 18(4): 308-311.